Previous pain response strongly predicted benefit from palliative reirradiation
Pain response after reirradiation was 60% in lesions that previously responded to RT versus 15% after primary nonresponse.
Tag
Reirradiation
Comprehensive radiotherapy tracked with longer survival in recurrent glioblastoma leptomeningeal dissemination
In recurrent IDH-wildtype glioblastoma LMD, comprehensive RT and systemic therapy were independently associated with longer survival.
CT lung-density changes may identify patient-specific radiosensitivity before thoracic re-irradiation
Normal-lung CT response was partly reproducible across RT courses, while short retreatment intervals increased response in previously irradiated lung.
HyperArc delivered stereotactic re-irradiation to 44 brain metastases after prior whole-brain RT
One patient underwent 21 Gy in three fractions to 44 recurrent brain metastases after WBRT, with rapid delivery and sustained local control.
Central lung re-irradiation achieved 80% one-year local control with limited severe toxicity
Central thoracic re-irradiation achieved 80.1% one-year local control, while cumulative esophageal V60 emerged as a potential toxicity signal.
BNCT achieved high response but limited local control in recurrent oral cancer re-irradiation
Accelerator-based BNCT produced an 80% response and 51.1% two-year survival, but two-year local control was 31.8% with substantial toxicity.
Hypofractionated proton re-irradiation remains promising but supported by limited evidence
Across 478 patients, hypofractionated proton re-irradiation showed encouraging site-specific outcomes, but heterogeneous retrospective evidence prevents firm conclusions on efficacy or safety.
ReCOG identifies major heterogeneity across pelvic re-irradiation trials
Nine prospective rectal and anal re-irradiation trials varied widely in dose, margins, cumulative-dose methods, organs at risk, and PRO reporting.
MR-guided prostate re-irradiation achieved high early control but accumulating GU toxicity
Failure-free survival was 96.6% at 12 months, while grade 3 GU toxicity increased to 12.5% by one year.
Stereotactic boost after recent radiotherapy achieved 86.5% one-year local control
A phase I study safely escalated five-fraction stereotactic boosts to 30-35 Gy after recent prior radiotherapy, with 86.5% one-year local control.
Breast re-irradiation achieved 84.2% five-year recurrence-free survival with 3.9% grade 3 toxicity
After resection of ipsilateral recurrence, five-year locoregional recurrence-free survival was 84.2%, while grade 3 late toxicity was 3.9%.
Third-course reirradiation provided symptom relief in selected patients with progressive DIPG
Across 12 reported patients receiving at least three radiation courses for DIPG, median survival was 27 months with frequent symptomatic benefit.
Proton hypofractionation achieved durable control in heavily reirradiated spine metastases
Proton hypofractionation produced 10% one-year local failure despite extensive prior irradiation, with grade 3 toxicity confined to multiply reirradiated patients.
Structured cumulative-dose review triggered replanning in one-quarter of proton reirradiation cases
Voxel-wise cumulative EQD2 review prompted reoptimization in 25.5% of proton reirradiation courses and exposed frequent registration problems.
Minibeam radiotherapy achieved 92% one-year local control in refractory superficial tumors
In the first clinical minibeam series, 86% had symptomatic improvement and one-year local control reached 92% with minibeam treatment alone.